Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.62 |
| ▸ | PPM1A | P35813 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497399 | 1.00 | PPM1B (0.62) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL4315591 | 1.00 | PPM1B (0.62) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL4315593 | 1.00 | PPM1B (0.62) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL27858195 | 0.75 | CYP1A2 (0.50) | PPM1BALPIPKMPTGS1XIAP | |
| SCHEMBL20576648 | 0.73 | PPM1B (0.41) | PPM1BPPM1AALPIPKMPTGS1 | |
| SCHEMBL31106393 | 0.71 | TRPA1 (0.51) | PPM1BALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1695172 | 0.67 | SLC1A3 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4992286 | 0.67 | ACE (0.42) | PPM1BALPIPKMPTGS1XIAP | |
| SCHEMBL8561050 | 0.66 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17905254 | 0.65 | MEN1 (0.46) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | NEURODERM LTD (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4460289-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | Neuroderm, Ltd. (IL) | 2024-11-13 | — | — | EP | disclosed |
| CN-118765198-A | Methods and compositions for treating parkinson's disease | 纽罗德姆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | NEURODERM, LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-11844754-B2 | Methods for treatment of Parkinson's disease | NEURODERM, LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| CN-116964069-A | Stabilized liquid compositions comprising levodopa-tyrosine conjugates and uses thereof | 纽罗德姆有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023126945-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-07-06 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844754-B2 | Methods for treatment of Parkinson's disease | DDC, DDT, SLC6A3 | PPM1B 522/4885PPM1A 795/4885ALPI 228/4885 |
| US-20240315997-A1 | METHOD OF TREATMENT OF PARKINSON’S DISEASE | DDC, DDT, COMT | PPM1B 364/4885PPM1A 626/4885ALPI 331/4885 |
| US-20250082595-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON’S DISEASE | DDC, COMT, DDT | PPM1B 294/4885PPM1A 405/4885ALPI 247/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | PPM1B 540/4885PPM1A 826/4885ALPI 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.